文献速递肝病消化道肿瘤与早癌

失代偿期肝硬化再代偿的患病率与临床结局:系统评价与荟萃分析

Prevalence and Clinical Outcomes of Recompensation in Decompensated Cirrhosis: A Systematic Review and Meta-Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2025-08-22

该系统评价与荟萃分析纳入27项研究共9063例失代偿期肝硬化患者,旨在明确再代偿的患病率及临床结局。结果显示再代偿总体合并患病率为35%,以HBV相关肝硬化最高(50%)、PBC相关最低(15%)。再代偿患者HCC发生、死亡及肝病相关死亡的比值均显著降低,肝移植比值相似。

要点

  • 失代偿期肝硬化病因控制后再代偿总体合并患病率为35%。
  • 再代偿在HBV相关肝硬化最常见(50%),PBC相关最少见(15%)。
  • 再代偿与HCC及死亡风险降低相关,可作为有临床意义的终点。

核心结论

  • 失代偿期肝硬化患者实现病因控制后约三分之一可发生再代偿。
  • 再代偿与HCC发生、死亡及肝病相关死亡风险降低相关,是临床有意义的终点。

研究设计与样本

  • 系统检索PubMed和EMBASE自建库至2025年7月15日的研究。
  • 纳入报告失代偿期肝硬化患者实现再代偿并评估临床结局的研究,共27项、9063例患者。

主要发现

  • 再代偿总体合并患病率为35%(95%CI 26%-45%;I2=98%;24项研究)。
  • HBV相关肝硬化再代偿患病率50%(95%CI 38%-61%;I2=99%;8项研究),PBC相关为15%(95%CI 4%-30%;I2=92%;3项研究)。
  • 再代偿患者HCC发生比值比0.55(95%CI 0.35-0.87;I2=12%;7项研究)。
  • 再代偿患者死亡比值比0.33(95%CI 0.19-0.58;I2=52%;9项研究),肝病相关死亡比值比0.21(95%CI 0.10-0.45;I2=36%;9项研究)。
  • 再代偿患者肝移植比值比0.34(95%CI 0.07-1.60;I2=0%;3项研究)。

临床怎么用

  • 对病因可控的失代偿期肝硬化患者,应积极病因治疗并监测再代偿。
  • 再代偿可作为评估治疗获益的临床终点,但仍需监测HCC发生。

局限性

  • 再代偿患病率各研究间异质性高(I2=98%)。
  • 再代偿与HCC、死亡等结局关联的证据确定性低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: The prevalence and clinical outcomes of recompensation in patients with decompensated cirrhosis remain unclear. We aimed to determine the prevalence and clinical outcomes among decompensated patients who achieve recompensation. METHODS: We systematically searched PubMed and EMBASE from inception until July 15, 2025. We included studies reporting on decompensated cirrhosis patients achieving recompensation to evaluate the clinical outcomes, specifically hepatocellular carcinoma (HCC), death, liver-related death, and liver transplantation, with those who did not recompensate. RESULTS: A total of 27 studies encompassing 9063 patients with decompensated cirrhosis were analyzed. The overall pooled prevalence of recompensation was 35% (95% confidence interval [CI], 26%-45%; I2 = 98%; 24 studies). Recompensation was most common in hepatitis B virus-related cirrhosis (50%; 95% CI, 38%-61%; I2 = 99%; 8 studies) and least common in primary biliary cholangitis-related cirrhosis (15%; 95% CI, 4%-30%; I2 = 92%; 3 studies). Low certainty evidence suggest that recompensated patients had significantly lower odds of HCC occurrence (odds ratio [OR], 0.55; 95% CI, 0.35-0.87; I2 = 12%; 7 studies), death (OR, 0.33; 95% CI, 0.19-0.58; I2 = 52%; 9 studies), and liver-related death (OR, 0.21; 95% CI, 0.10-0.45; I2 = 36%; 9 studies), with similar odds of liver transplantation (OR, 0.34; 95% CI, 0.07-1.60; I2 = 0%; 3 studies). CONCLUSIONS: Recompensation occurred in approximately one-third of decompensated cirrhosis patients who achieved etiological control. Recompensation was associated with lower risk of HCC and death, and thus represents a clinically meaningful endpoint in this population.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Goh XE, Goh MX, Chen VL, et al. Prevalence and Clinical Outcomes of Recompensation in Decompensated Cirrhosis: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2025. PMID: 40848912. doi:10.1016/j.cgh.2025.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。